nach oben

Erschienen in:

01.01.2012 | Review and Perspectives

Personalized cancer medicine and the future of pathology

verfasst von: H. Moch, P. R. Blank, M. Dietel, G. Elmberger, K. M. Kerr, J. Palacios, F. Penault-Llorca, G. Rossi, T. D. Szucs

Erschienen in: Virchows Archiv | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

In February 2011, a group of pathologists from different departments in Europe met in Zurich, Switzerland, to discuss opportunities and challenges for pathology in the era of personalized medicine. The major topics of the meeting were assessment of the role of pathology in personalized medicine, its future profile among other biomedical disciplines with an interest in personalized medicine as well as the evolution of companion diagnostics. The relevance of novel technologies for genome analysis in clinical practice was discussed. The participants recognize that there should be more initiatives taken by the pathology community in companion diagnostics and in the emerging field of next-generation sequencing and whole genome analysis. The common view of the participants was that the pathology community has to be mobilized for stronger engagement in the future of personalized medicine. Pathologists should be aware of the challenges and the analytical opportunities of the new technologies. Challenges of clinical trial design as well as insurance and reimbursement questions were addressed. The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics.

Stricker T, Catenacci DV, Seiwert TY (2011) Molecular profiling of cancer—the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 38:173–185PubMedCrossRef

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMedCrossRef

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRef

Hortobagyi GN (2005) Trastuzumab in the treatment of breast cancer. N Engl J Med 353:1734–1736PubMedCrossRef

Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369:1731–1741PubMedCrossRef

Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRef

Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRef

Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819PubMedCrossRef

10.

Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566PubMedCrossRef

11.

Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634PubMedCrossRef

12.

Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27:1130–1136PubMedCrossRef

13.

Gabrielson E, Berg K, Anbazhagan R (2001) Functional genomics, gene arrays, and the future of pathology. Mod Pathol 14:1294–1299PubMedCrossRef

14.

Anonymous (2011) Getting personal. Nature 473:253–254

15.

Luciano JS, Andersson B, Batchelor C et al (2011) The translational medicine ontology and knowledge base: driving personalized medicine by bridging the gap between bench and bedside. J Biomed Semantics 2(Suppl 2):S1PubMedCrossRef

16.

Dahinden C, Ingold B, Wild P et al (2010) Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 16:88–98PubMedCrossRef

17.

Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806PubMedCrossRef

18.

Carracedo A, Ma L, Teruya-Feldstein J et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065–3074PubMed

19.

Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE (2011) A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the Banbury Conference Center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am J Clin Pathol 135:668–672PubMedCrossRef

20.

Salzberg SL, Pertea M (2010) Do-it-yourself genetic testing. Genome Biol 11:404PubMedCrossRef

21.

Blank PR, Moch H, Szucs TD, Schwenkglenks M (2011) KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 17:6338–6346PubMedCrossRef

22.

Blank PR, Schwenkglenks M, Moch H, Szucs TD (2010) Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat 124:497–507PubMedCrossRef

23.

Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef

24.

Blank PR, Dedes KJ, Szucs TD (2010) Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. PharmacoEconomics 28:629–647PubMedCrossRef

25.

Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol 28:466–474PubMedCrossRef

26.

Palanisamy N, Ateeq B, Kalyana-Sundaram S et al (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793–798PubMedCrossRef

27.

AMP Whole Genome Analysis Working Group (2011) The Association for Molecular Pathology’s approach to supporting a global agenda to embrace personalized genomic medicine. J Mol Diagn 13:249–251CrossRef

28.

Dietel M, Sers C (2006) Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 448:744–755PubMedCrossRef

29.

Pirker R, Herth FJ, Kerr KM et al (2010) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5:1706–1713PubMedCrossRef

30.

Marchetti A, Normanno N, Pinto C et al (2010) Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 102:119–126PubMed

31.

Kulesza P, Ramchandran K, Patel JD (2011) Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol 136:228–238PubMedCrossRef

32.

van Krieken JH, Jung A, Kirchner T et al (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417–431PubMedCrossRef

33.

Macconaill LE, Van Hummelen P, Meyerson M, Hahn WC (2011) Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov 1:297PubMedCrossRef

34.

Cagle PT, Allen TC, Dacic S et al (2011) Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 135:110–116PubMed

35.

Kerr K (2011) Personalized medicine for lung cancer: new challenges for pathology. Histopathology. doi:10.1111/j.1365-2559.2011.03854.x

Titel: Personalized cancer medicine and the future of pathology
verfasst von: H. Moch
P. R. Blank
M. Dietel
G. Elmberger
K. M. Kerr
J. Palacios
F. Penault-Llorca
G. Rossi
T. D. Szucs
Publikationsdatum: 01.01.2012
Verlag: Springer-Verlag
Erschienen in: Virchows Archiv / Ausgabe 1/2012
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-011-1179-6

Springer Medizin

Personalized cancer medicine and the future of pathology

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Peripheral chondrosarcoma progression is associated with increased type X collagen and vascularisation

Eosinophilic myenteric ganglionitis as a cause of chronic intestinal pseudo-obstruction

Expression of Raf-1 kinase inhibitory protein in carcinoma of the ampulla of Vater

Fatty lesions in intra-articular loose bodies: a histopathological study of non-primary synovial chondromatosis cases

CD99 is expressed in chordoid glioma and suggests ependymal origin

Frozen section analysis of sentinel lymph nodes in patients with breast cancer does not impair the probability to detect lymph node metastases

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie